10-Q 1 mrk-20220930.htm 10-Q mrk-20220930
FALSE2022Q3000031015812/310.10000http://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesNoncurrenthttp://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2022#DeferredIncomeTaxesAndOtherAssetsCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherLiabilitiesCurrenthttp://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpensehttp://fasb.org/us-gaap/2022#OtherNonoperatingIncomeExpenseP1D00003101582022-01-012022-09-300000310158us-gaap:CommonStockMember2022-01-012022-09-300000310158mrk:A0.500Notesdue2024Member2022-01-012022-09-300000310158mrk:A1.875Notesdue2026Member2022-01-012022-09-300000310158mrk:A2.500Notesdue2034Member2022-01-012022-09-300000310158mrk:A1.375Notesdue2036Member2022-01-012022-09-3000003101582022-10-31xbrli:shares00003101582022-07-012022-09-30iso4217:USD00003101582021-07-012021-09-3000003101582021-01-012021-09-30iso4217:USDxbrli:shares00003101582022-09-3000003101582021-12-3100003101582020-12-3100003101582021-09-300000310158mrk:OrganonCoMember2021-06-0200003101582021-06-020000310158mrk:TransitionServicesAgreementMembersrt:MinimumMember2021-06-022021-06-020000310158mrk:TransitionServicesAgreementMembersrt:MaximumMember2021-06-022021-06-020000310158srt:MinimumMembermrk:ManufacturingAndSupplyAgreementsMember2021-06-022021-06-020000310158srt:MaximumMembermrk:ManufacturingAndSupplyAgreementsMember2021-06-022021-06-020000310158mrk:OrganonCoMember2022-07-012022-09-300000310158mrk:OrganonCoMember2022-01-012022-09-300000310158mrk:OrganonCoMember2022-09-300000310158mrk:OrganonCoMember2021-12-310000310158mrk:OrganonCoMember2021-06-022021-06-02xbrli:pure0000310158mrk:OrganonCoMember2021-07-012021-09-300000310158mrk:OrganonCoMember2021-01-012021-09-300000310158us-gaap:SubsequentEventMember2022-10-012022-10-310000310158us-gaap:LicensingAgreementsMembermrk:OrnaTherapeuticsMember2022-08-012022-08-310000310158mrk:DevelopmentMilestonesMemberus-gaap:LicensingAgreementsMembermrk:OrnaTherapeuticsMember2022-08-012022-08-310000310158us-gaap:LicensingAgreementsMembermrk:RegulatoryMilestonesMembermrk:OrnaTherapeuticsMember2022-08-012022-08-310000310158us-gaap:LicensingAgreementsMembermrk:SalesBasedMilestonesMembermrk:OrnaTherapeuticsMember2022-08-012022-08-310000310158us-gaap:SubsequentEventMembermrk:OrnaTherapeuticsMember2022-10-012022-12-310000310158mrk:OrionCorporationMemberus-gaap:LicensingAgreementsMember2022-07-012022-07-310000310158us-gaap:LicensingAgreementsMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember2022-07-012022-07-310000310158mrk:DevelopmentMilestonesMemberus-gaap:LicensingAgreementsMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember2022-07-012022-07-310000310158us-gaap:LicensingAgreementsMembermrk:RegulatoryMilestonesMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember2022-07-012022-07-310000310158us-gaap:LicensingAgreementsMembermrk:SalesBasedMilestonesMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember2022-07-012022-07-310000310158us-gaap:LicensingAgreementsMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember2022-05-012022-05-310000310158mrk:DevelopmentMilestonesMemberus-gaap:LicensingAgreementsMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember2022-05-012022-05-310000310158mrk:FirstCommercialSaleMilestonesMemberus-gaap:LicensingAgreementsMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember2022-05-012022-05-310000310158us-gaap:LicensingAgreementsMembermrk:SalesBasedMilestonesMembermrk:SichuanKelunBiotechBiopharmaceuticalCoLtdMember2022-05-012022-05-310000310158mrk:PandionTherapeuticsMember2021-04-012021-04-300000310158mrk:PandionTherapeuticsMember2021-04-300000310158mrk:PandionTherapeuticsMember2021-01-012021-09-300000310158mrk:ArtivaBiotherapeuticsIncMemberus-gaap:LicensingAgreementsMember2021-01-012021-01-31mrk:research_programmrk:collaboration_target0000310158mrk:ArtivaBiotherapeuticsIncMembermrk:DevelopmentMilestonesMemberus-gaap:LicensingAgreementsMember2021-01-012021-01-310000310158mrk:ArtivaBiotherapeuticsIncMemberus-gaap:LicensingAgreementsMembermrk:RegulatoryMilestonesMember2021-01-012021-01-310000310158mrk:ArtivaBiotherapeuticsIncMemberus-gaap:LicensingAgreementsMembermrk:SalesBasedMilestonesMember2021-01-012021-01-310000310158mrk:ArtivaBiotherapeuticsIncMembersrt:MinimumMemberus-gaap:LicensingAgreementsMember2021-01-012021-01-310000310158mrk:ArtivaBiotherapeuticsIncMemberus-gaap:LicensingAgreementsMembersrt:MaximumMember2021-01-012021-01-310000310158mrk:COVID19Member2021-01-012021-09-300000310158mrk:SalesBasedMilestonesMembermrk:LynparzaMembermrk:AstraZenecaMember2022-01-012022-03-310000310158mrk:SalesBasedMilestonesMembermrk:LynparzaMembermrk:AstraZenecaMember2022-03-310000310158mrk:LynparzaMember2022-01-012022-03-310000310158mrk:LynparzaMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-09-300000310158mrk:SalesBasedMilestonesMembermrk:LynparzaMembermrk:AstraZenecaMember2022-09-300000310158mrk:LynparzaMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-09-300000310158us-gaap:OtherNoncurrentAssetsMembermrk:LynparzaMember2022-09-300000310158us-gaap:SalesMembermrk:AstraZenecaMembermrk:AlliancerevenueLynparzaMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158us-gaap:SalesMembermrk:AstraZenecaMembermrk:AlliancerevenueLynparzaMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158us-gaap:SalesMembermrk:AstraZenecaMembermrk:AlliancerevenueLynparzaMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158us-gaap:SalesMembermrk:AstraZenecaMembermrk:AlliancerevenueLynparzaMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158us-gaap:SalesMembermrk:AstraZenecaMembermrk:AllianceRevenueKoselugoMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158us-gaap:SalesMembermrk:AstraZenecaMembermrk:AllianceRevenueKoselugoMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158us-gaap:SalesMembermrk:AstraZenecaMembermrk:AllianceRevenueKoselugoMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158us-gaap:SalesMembermrk:AstraZenecaMembermrk:AllianceRevenueKoselugoMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158us-gaap:SalesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158us-gaap:SalesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158us-gaap:SalesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158us-gaap:SalesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158mrk:AstraZenecaMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158mrk:AstraZenecaMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158mrk:AstraZenecaMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158mrk:AstraZenecaMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158mrk:AstraZenecaMemberus-gaap:OtherCurrentAssetsMemberus-gaap:CollaborativeArrangementMember2022-09-300000310158mrk:AstraZenecaMemberus-gaap:OtherCurrentAssetsMemberus-gaap:CollaborativeArrangementMember2021-12-310000310158mrk:AstraZenecaMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CollaborativeArrangementMember2022-09-300000310158mrk:AstraZenecaMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CollaborativeArrangementMember2021-12-310000310158us-gaap:OtherNoncurrentLiabilitiesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2022-09-300000310158us-gaap:OtherNoncurrentLiabilitiesMembermrk:AstraZenecaMemberus-gaap:CollaborativeArrangementMember2021-12-310000310158mrk:EisaiMember2021-03-012021-03-310000310158mrk:LenvimaMembermrk:EisaiMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-09-300000310158mrk:LenvimaMembermrk:EisaiMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-09-300000310158mrk:LenvimaMemberus-gaap:OtherNoncurrentAssetsMember2022-09-300000310158mrk:EisaiMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158mrk:EisaiMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158mrk:EisaiMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158mrk:EisaiMemberus-gaap:SalesMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158mrk:EisaiMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158mrk:EisaiMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158mrk:EisaiMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158mrk:EisaiMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158mrk:EisaiMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158mrk:EisaiMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158mrk:EisaiMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158mrk:EisaiMemberus-gaap:SellingGeneralAndAdministrativeExpensesMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158mrk:EisaiMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158mrk:EisaiMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158mrk:EisaiMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158mrk:EisaiMemberus-gaap:ResearchAndDevelopmentExpenseMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158mrk:EisaiMemberus-gaap:OtherCurrentAssetsMemberus-gaap:CollaborativeArrangementMember2022-09-300000310158mrk:EisaiMemberus-gaap:OtherCurrentAssetsMemberus-gaap:CollaborativeArrangementMember2021-12-310000310158mrk:EisaiMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CollaborativeArrangementMember2022-09-300000310158mrk:EisaiMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CollaborativeArrangementMember2021-12-310000310158mrk:BayerAGMemberus-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember2022-01-012022-01-310000310158us-gaap:OtherIntangibleAssetsMembermrk:AdempasMember2022-09-300000310158mrk:VerquvoMemberus-gaap:OtherIntangibleAssetsMember2022-09-300000310158us-gaap:SalesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158us-gaap:SalesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158us-gaap:SalesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158us-gaap:SalesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158us-gaap:SalesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMembermrk:AdempasMember2022-07-012022-09-300000310158us-gaap:SalesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMembermrk:AdempasMember2021-07-012021-09-300000310158us-gaap:SalesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMembermrk:AdempasMember2022-01-012022-09-300000310158us-gaap:SalesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMembermrk:AdempasMember2021-01-012021-09-300000310158mrk:VerquvoMemberus-gaap:SalesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158mrk:VerquvoMemberus-gaap:SalesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158mrk:VerquvoMemberus-gaap:SalesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158mrk:VerquvoMemberus-gaap:SalesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158mrk:BayerAGMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158mrk:BayerAGMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158mrk:BayerAGMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158mrk:BayerAGMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:BayerAGMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158mrk:BayerAGMemberus-gaap:OtherCurrentAssetsMemberus-gaap:CollaborativeArrangementMember2022-09-300000310158mrk:BayerAGMemberus-gaap:OtherCurrentAssetsMemberus-gaap:CollaborativeArrangementMember2021-12-310000310158mrk:BayerAGMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CollaborativeArrangementMember2022-09-300000310158mrk:BayerAGMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CollaborativeArrangementMember2021-12-31mrk:marketmrk:course0000310158us-gaap:SalesMembermrk:LagevrioMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158us-gaap:SalesMembermrk:LagevrioMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158us-gaap:SalesMembermrk:LagevrioMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158us-gaap:SalesMembermrk:LagevrioMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:CostOfSalesMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2022-07-012022-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2021-07-012021-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2022-01-012022-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMembermrk:RidgebackBiotherapeuticsLPMemberus-gaap:CollaborativeArrangementMember2021-01-012021-09-300000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CollaborativeArrangementMember2022-09-300000310158mrk:RidgebackBiotherapeuticsLPMemberus-gaap:AccountsPayableAndAccruedLiabilitiesMemberus-gaap:CollaborativeArrangementMember2021-12-310000310158srt:MinimumMemberus-gaap:LicensingAgreementsMembermrk:BristolMyersSquibbMember2022-01-012022-09-300000310158us-gaap:LicensingAgreementsMembersrt:MaximumMembermrk:BristolMyersSquibbMember2022-01-012022-09-300000310158us-gaap:LicensingAgreementsMembermrk:BristolMyersSquibbMember2022-01-012022-09-300000310158us-gaap:LicensingAgreementsMembermrk:SalesBasedMilestonesMembermrk:BristolMyersSquibbMember2022-01-012022-09-300000310158mrk:AllianceRevenueReblozylMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:AllianceRevenueReblozylMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158us-gaap:LicensingAgreementsMembermrk:BristolMyersSquibbMembermrk:RegulatoryMilestonesMember2022-01-012022-09-300000310158srt:ScenarioForecastMember2022-12-310000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:CostOfSalesMember2022-07-012022-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:CostOfSalesMember2022-07-012022-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:CostOfSalesMember2022-07-012022-09-300000310158us-gaap:CostOfSalesMember2022-07-012022-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:CostOfSalesMember2022-01-012022-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:CostOfSalesMember2022-01-012022-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:CostOfSalesMember2022-01-012022-09-300000310158us-gaap:CostOfSalesMember2022-01-012022-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012022-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012022-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012022-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-07-012022-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMember2022-07-012022-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:RestructuringChargesMember2022-07-012022-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:RestructuringChargesMember2022-07-012022-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:RestructuringChargesMember2022-07-012022-09-300000310158us-gaap:RestructuringChargesMember2022-07-012022-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:RestructuringChargesMember2022-01-012022-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:RestructuringChargesMember2022-01-012022-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:RestructuringChargesMember2022-01-012022-09-300000310158us-gaap:RestructuringChargesMember2022-01-012022-09-300000310158us-gaap:OneTimeTerminationBenefitsMember2022-07-012022-09-300000310158mrk:AcceleratedDepreciationMember2022-07-012022-09-300000310158us-gaap:OtherRestructuringMember2022-07-012022-09-300000310158us-gaap:OneTimeTerminationBenefitsMember2022-01-012022-09-300000310158mrk:AcceleratedDepreciationMember2022-01-012022-09-300000310158us-gaap:OtherRestructuringMember2022-01-012022-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:CostOfSalesMember2021-07-012021-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:CostOfSalesMember2021-07-012021-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:CostOfSalesMember2021-07-012021-09-300000310158us-gaap:CostOfSalesMember2021-07-012021-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:CostOfSalesMember2021-01-012021-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:CostOfSalesMember2021-01-012021-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:CostOfSalesMember2021-01-012021-09-300000310158us-gaap:CostOfSalesMember2021-01-012021-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2021-07-012021-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2021-07-012021-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2021-07-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-07-012021-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-09-300000310158us-gaap:SellingGeneralAndAdministrativeExpensesMember2021-01-012021-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMember2021-07-012021-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300000310158us-gaap:ResearchAndDevelopmentExpenseMember2021-01-012021-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:RestructuringChargesMember2021-07-012021-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:RestructuringChargesMember2021-07-012021-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:RestructuringChargesMember2021-07-012021-09-300000310158us-gaap:RestructuringChargesMember2021-07-012021-09-300000310158us-gaap:OneTimeTerminationBenefitsMemberus-gaap:RestructuringChargesMember2021-01-012021-09-300000310158mrk:AcceleratedDepreciationMemberus-gaap:RestructuringChargesMember2021-01-012021-09-300000310158us-gaap:OtherRestructuringMemberus-gaap:RestructuringChargesMember2021-01-012021-09-300000310158us-gaap:RestructuringChargesMember2021-01-012021-09-300000310158us-gaap:OneTimeTerminationBenefitsMember2021-07-012021-09-300000310158mrk:AcceleratedDepreciationMember2021-07-012021-09-300000310158us-gaap:OtherRestructuringMember2021-07-012021-09-300000310158us-gaap:OneTimeTerminationBenefitsMember2021-01-012021-09-300000310158mrk:AcceleratedDepreciationMember2021-01-012021-09-300000310158us-gaap:OtherRestructuringMember2021-01-012021-09-300000310158us-gaap:OneTimeTerminationBenefitsMember2021-12-310000310158mrk:AcceleratedDepreciationMember2021-12-310000310158us-gaap:OtherRestructuringMember2021-12-310000310158us-gaap:OneTimeTerminationBenefitsMember2022-09-300000310158mrk:AcceleratedDepreciationMember2022-09-300000310158us-gaap:OtherRestructuringMember2022-09-300000310158us-gaap:DesignatedAsHedgingInstrumentMembersrt:MaximumMember2022-01-012022-09-300000310158srt:MaximumMemberus-gaap:NondesignatedMember2022-01-012022-09-300000310158us-gaap:ForeignExchangeContractMember2022-07-012022-09-300000310158us-gaap:ForeignExchangeContractMember2021-07-012021-09-300000310158us-gaap:ForeignExchangeContractMember2022-01-012022-09-300000310158us-gaap:ForeignExchangeContractMember2021-01-012021-09-300000310158us-gaap:ForeignExchangeContractMemberus-gaap:OtherNonoperatingIncomeExpenseMember2022-07-012022-09-300000310158us-gaap:ForeignExchangeContractMemberus-gaap:OtherNonoperatingIncomeExpenseMember2021-07-012021-09-300000310158us-gaap:ForeignExchangeContractMemberus-gaap:OtherNonoperatingIncomeExpenseMember2022-01-012022-09-300000310158us-gaap:ForeignExchangeContractMemberus-gaap:OtherNonoperatingIncomeExpenseMember2021-01-012021-09-300000310158mrk:EurodominatedNotesMember2022-07-012022-09-300000310158mrk:EurodominatedNotesMember2021-07-012021-09-300000310158mrk:EurodominatedNotesMember2022-01-012022-09-300000310158mrk:EurodominatedNotesMember2021-01-012021-09-300000310158mrk:EurodominatedNotesMemberus-gaap:OtherNonoperatingIncomeExpenseMember2022-07-012022-09-300000310158mrk:EurodominatedNotesMemberus-gaap:OtherNonoperatingIncomeExpenseMember2021-07-012021-09-300000310158mrk:EurodominatedNotesMemberus-gaap:OtherNonoperatingIncomeExpenseMember2022-01-012022-09-300000310158mrk:EurodominatedNotesMemberus-gaap:OtherNonoperatingIncomeExpenseMember2021-01-012021-09-300000310158us-gaap:InterestRateSwapMember2022-02-28mrk:interest_rate_swap0000310158mrk:A2.35NotesDue2022Memberus-gaap:InterestRateSwapMember2022-02-280000310158mrk:A2.35NotesDue2022Member2022-02-280000310158us-gaap:InterestRateSwapMember2022-09-300000310158mrk:A2.40NotesDue2022Memberus-gaap:InterestRateSwapMember2022-09-300000310158mrk:A2.40NotesDue2022Member2022-09-300000310158mrk:A2.40NotesDue2022Member2022-09-300000310158mrk:LongTermDebtCurrentMaturitiesMember2022-09-300000310158mrk:LongTermDebtCurrentMaturitiesMember2021-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMember2021-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMember2022-09-300000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMembermrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember2022-09-300000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMembermrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember2021-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMembermrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember2022-09-300000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMembermrk:DeferredIncomeTaxesAndOtherAssetsCurrentMember2021-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMembermrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMemberus-gaap:ForeignExchangeContractMember2022-09-300000310158us-gaap:DesignatedAsHedgingInstrumentMembermrk:DeferredIncomeTaxesAndOtherAssetsNoncurrentMemberus-gaap:ForeignExchangeContractMember2021-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMember2021-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMember2022-09-300000310158us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2022-09-300000310158us-gaap:OtherNoncurrentLiabilitiesMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2021-12-310000310158us-gaap:DesignatedAsHedgingInstrumentMember2022-09-300000310158us-gaap:DesignatedAsHedgingInstrumentMember2021-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2022-09-300000310158us-gaap:ForeignExchangeContractMemberus-gaap:NondesignatedMember2021-12-310000310158us-gaap:ForeignExchangeContractMembermrk:DeferredIncomeTaxesAndOtherAssetsCurrentMemberus-gaap:NondesignatedMember2022-09-300000310158us-gaap:ForeignExchangeContractMembermrk:DeferredIncomeTaxesAndOtherAssetsCurrentMemberus-gaap:NondesignatedMember2021-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:NondesignatedMember2022-09-300000310158us-gaap:ForeignExchangeContractMemberus-gaap:OtherCurrentLiabilitiesMemberus-gaap:NondesignatedMember2021-12-310000310158us-gaap:NondesignatedMember2022-09-300000310158us-gaap:NondesignatedMember2021-12-310000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2022-07-012022-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2021-07-012021-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2022-01-012022-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:InterestRateSwapMember2021-01-012021-09-300000310158us-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-07-012022-09-300000310158us-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-07-012021-09-300000310158us-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2022-01-012022-09-300000310158us-gaap:ForeignExchangeContractMemberus-gaap:ReclassificationOutOfAccumulatedOtherComprehensiveIncomeMemberus-gaap:AccumulatedGainLossCashFlowHedgeIncludingNoncontrollingInterestMember2021-01-012021-09-300000310158us-gaap:InterestRateSwapMember2022-07-012022-09-300000310158us-gaap:InterestRateSwapMember2021-07-012021-09-300000310158us-gaap:InterestRateSwapMember2022-01-012022-09-300000310158us-gaap:InterestRateSwapMember2021-01-012021-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:CurrencySwapMember2022-07-012022-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:CurrencySwapMember2021-07-012021-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:CurrencySwapMember2022-01-012022-09-300000310158us-gaap:OtherNonoperatingIncomeExpenseMemberus-gaap:CurrencySwapMember2021-01-012021-09-300000310158us-gaap:SalesMemberus-gaap:ForeignExchangeFutureMember2022-07-012022-09-300000310158us-gaap:SalesMemberus-gaap:ForeignExchangeFutureMember2021-07-012021-09-300000310158us-gaap:SalesMemberus-gaap:ForeignExchangeFutureMember2022-01-012022-09-300000310158us-gaap:SalesMemberus-gaap:ForeignExchangeFutureMember2021-01-012021-09-300000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-09-300000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310000310158us-gaap:CommercialPaperMember2022-09-300000310158us-gaap:CommercialPaperMember2021-12-310000310158us-gaap:CorporateDebtSecuritiesMember2022-09-300000310158us-gaap:CorporateDebtSecuritiesMember2021-12-310000310158us-gaap:ForeignGovernmentDebtSecuritiesMember2022-09-300000310158us-gaap:ForeignGovernmentDebtSecuritiesMember2021-12-310000310158us-gaap:EquityFundsMember2022-07-012022-09-300000310158us-gaap:EquityFundsMember2021-07-012021-09-300000310158us-gaap:EquityFundsMember2022-01-012022-09-300000310158us-gaap:EquityFundsMember2021-01-012021-09-300000310158us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:FairValueInputsLevel1Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:CommercialPaperMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2022-09-300000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2022-09-300000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2022-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2022-09-300000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2021-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2021-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2021-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMember2021-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:FairValueInputsLevel1Memberus-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:EquitySecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:USGovernmentAgenciesDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:CorporateDebtSecuritiesMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:ForeignExchangeContractMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueMeasurementsRecurringMember2022-09-300000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:ForeignExchangeOptionMemberus-gaap:FairValueMeasurementsRecurringMember2021-12-310000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2022-09-300000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2022-09-300000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2022-09-300000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2022-09-300000310158us-gaap:FairValueInputsLevel1Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2021-12-310000310158us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2021-12-310000310158us-gaap:FairValueInputsLevel3Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2021-12-310000310158us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateSwapMember2021-12-310000310158us-gaap:FairValueInputsLevel2Member2022-09-300000310158us-gaap:FairValueInputsLevel2Member2021-12-310000310158mrk:SanofiPasteurMember2022-09-3000003101582021-01-012021-12-310000310158mrk:InventoryNotExpectedtobeSoldWithinOneYearMember2022-09-300000310158mrk:InventoryNotExpectedtobeSoldWithinOneYearMember2021-12-310000310158mrk:InventoriesProducedinPreparationforProductLaunchesMember2022-09-300000310158mrk:InventoriesProducedinPreparationforProductLaunchesMember2021-12-310000310158us-gaap:InProcessResearchAndDevelopmentMember2022-07-012022-09-300000310158mrk:NemtabrutinibMemberus-gaap:InProcessResearchAndDevelopmentMember2022-07-012022-09-300000310158mrk:NemtabrutinibMemberus-gaap:InProcessResearchAndDevelopmentMember2022-09-300000310158mrk:FosamaxMember2022-09-30mrk:case0000310158mrk:FosamaxMembermrk:FederalMembermrk:FemurFractureLitigationMember2014-03-012014-03-310000310158mrk:JanuviaMembermrk:CasesCompanyAgreedToTollStatuteOfLimitationsMember2022-09-30mrk:claim0000310158country:USmrk:GardasilGardasil9Member2022-09-300000310158mrk:GardasilGardasil9Memberus-gaap:NonUsMember2022-09-300000310158mrk:GardasilGardasil9Membercountry:CO2022-09-300000310158mrk:ZetiaantitrustlitigationMember2020-08-310000310158us-gaap:PendingLitigationMembermrk:ZetiaantitrustlitigationMember2022-06-302022-06-300000310158us-gaap:PatentsMembermrk:BridionMemberus-gaap:PendingLitigationMembersrt:ScenarioForecastMember2022-12-192022-12-190000310158us-gaap:PatentsMembermrk:BridionMember2022-01-012022-09-300000310158us-gaap:PatentsMembermrk:BridionMemberus-gaap:PendingLitigationMember2022-09-300000310158us-gaap:PatentsMembermrk:JanuviaAndJanumetMember2022-01-012022-09-300000310158us-gaap:PendingLitigationMembersrt:ScenarioForecastMembermrk:PatentInfringementLawsuitAgainstZydusWorldwideDMCCZydusPharmaceuticalsUSAIncAndCadilaHealthcareLtdMember2023-01-092023-01-090000310158mrk:LegalDefenseCostsMember2022-09-300000310158mrk:LegalDefenseCostsMember2021-12-310000310158us-gaap:CommonStockMember2021-06-300000310158us-gaap:AdditionalPaidInCapitalMember2021-06-300000310158us-gaap:RetainedEarningsMember2021-06-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-06-300000310158us-gaap:TreasuryStockCommonMember2021-06-300000310158us-gaap:NoncontrollingInterestMember2021-06-3000003101582021-06-300000310158us-gaap:RetainedEarningsMember2021-07-012021-09-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-07-012021-09-300000310158us-gaap:TreasuryStockCommonMember2021-07-012021-09-300000310158us-gaap:AdditionalPaidInCapitalMember2021-07-012021-09-300000310158us-gaap:NoncontrollingInterestMember2021-07-012021-09-300000310158us-gaap:CommonStockMember2021-09-300000310158us-gaap:AdditionalPaidInCapitalMember2021-09-300000310158us-gaap:RetainedEarningsMember2021-09-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-09-300000310158us-gaap:TreasuryStockCommonMember2021-09-300000310158us-gaap:NoncontrollingInterestMember2021-09-300000310158us-gaap:CommonStockMember2022-06-300000310158us-gaap:AdditionalPaidInCapitalMember2022-06-300000310158us-gaap:RetainedEarningsMember2022-06-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-06-300000310158us-gaap:TreasuryStockCommonMember2022-06-300000310158us-gaap:NoncontrollingInterestMember2022-06-3000003101582022-06-300000310158us-gaap:RetainedEarningsMember2022-07-012022-09-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-012022-09-300000310158us-gaap:AdditionalPaidInCapitalMember2022-07-012022-09-300000310158us-gaap:TreasuryStockCommonMember2022-07-012022-09-300000310158us-gaap:NoncontrollingInterestMember2022-07-012022-09-300000310158us-gaap:CommonStockMember2022-09-300000310158us-gaap:AdditionalPaidInCapitalMember2022-09-300000310158us-gaap:RetainedEarningsMember2022-09-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-09-300000310158us-gaap:TreasuryStockCommonMember2022-09-300000310158us-gaap:NoncontrollingInterestMember2022-09-300000310158us-gaap:CommonStockMember2020-12-310000310158us-gaap:AdditionalPaidInCapitalMember2020-12-310000310158us-gaap:RetainedEarningsMember2020-12-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310000310158us-gaap:TreasuryStockCommonMember2020-12-310000310158us-gaap:NoncontrollingInterestMember2020-12-310000310158us-gaap:RetainedEarningsMember2021-01-012021-09-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-09-300000310158us-gaap:TreasuryStockCommonMember2021-01-012021-09-300000310158us-gaap:AdditionalPaidInCapitalMember2021-01-012021-09-300000310158us-gaap:NoncontrollingInterestMember2021-01-012021-09-300000310158us-gaap:CommonStockMember2021-12-310000310158us-gaap:AdditionalPaidInCapitalMember2021-12-310000310158us-gaap:RetainedEarningsMember2021-12-310000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000310158us-gaap:TreasuryStockCommonMember2021-12-310000310158us-gaap:NoncontrollingInterestMember2021-12-310000310158us-gaap:RetainedEarningsMember2022-01-012022-09-300000310158us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-09-300000310158us-gaap:AdditionalPaidInCapitalMember2022-01-012022-09-300000310158us-gaap:TreasuryStockCommonMember2022-01-012022-09-300000310158us-gaap:NoncontrollingInterestMember2022-01-012022-09-300000310158us-gaap:PensionPlansDefinedBenefitMember2022-01-012022-09-300000310158country:USus-gaap:PensionPlansDefinedBenefitMember2022-07-012022-09-300000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2022-07-012022-09-300000310158country:USus-gaap:PensionPlansDefinedBenefitMember2021-07-012021-09-300000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2021-07-012021-09-300000310158country:USus-gaap:PensionPlansDefinedBenefitMember2022-01-012022-09-300000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2022-01-012022-09-300000310158country:USus-gaap:PensionPlansDefinedBenefitMember2021-01-012021-09-300000310158us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2021-01-012021-09-300000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-09-300000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-07-012022-09-300000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-07-012021-09-300000310158us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2021-01-012021-09-300000310158us-gaap:DomesticCountryMemberus-gaap:SegmentContinuingOperationsMemberus-gaap:InternalRevenueServiceIRSMember2021-01-012021-09-300000310158us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMember2021-01-012021-03-310000310158us-gaap:DomesticCountryMemberus-gaap:SegmentContinuingOperationsMemberus-gaap:InternalRevenueServiceIRSMember2021-01-012021-03-310000310158us-gaap:DomesticCountryMemberus-gaap:SegmentDiscontinuedOperationsMemberus-gaap:InternalRevenueServiceIRSMember2021-01-012021-03-310000310158us-gaap:DomesticCountryMemberus-gaap:InternalRevenueServiceIRSMember2021-01-012021-09-300000310158us-gaap:DomesticCountryMemberus-gaap:SegmentDiscontinuedOperationsMemberus-gaap:InternalRevenueServiceIRSMember2021-01-012021-09-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-06-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-06-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2021-06-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-07-012021-09-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-07-012021-09-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2021-07-012021-09-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-09-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-09-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2021-09-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-06-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-06-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2022-06-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-07-012022-09-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-07-012022-09-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2022-07-012022-09-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-09-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-09-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2022-09-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2020-12-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2020-12-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2020-12-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-01-012021-09-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-01-012021-09-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2021-01-012021-09-300000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2021-12-310000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2021-12-310000310158us-gaap:AccumulatedTranslationAdjustmentMember2021-12-310000310158us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-01-012022-09-300000310158us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2022-01-012022-09-300000310158us-gaap:AccumulatedTranslationAdjustmentMember2022-01-012022-09-30mrk:segment0000310158country:USmrk:KeytrudaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:KeytrudaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:KeytrudaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:KeytrudaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:KeytrudaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:KeytrudaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:KeytrudaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:KeytrudaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:KeytrudaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:KeytrudaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:KeytrudaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:KeytrudaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:AlliancerevenueLynparzaMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:AlliancerevenueLynparzaMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:AlliancerevenueLynparzaMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:AlliancerevenueLynparzaMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:AlliancerevenueLynparzaMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:LenvimaMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:LenvimaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:LenvimaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:LenvimaMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:LenvimaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:LenvimaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:LenvimaMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:LenvimaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:LenvimaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:LenvimaMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:LenvimaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:LenvimaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:AllianceRevenueReblozylMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:AllianceRevenueReblozylMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:AllianceRevenueReblozylMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:AllianceRevenueReblozylMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:AllianceRevenueReblozylMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:AllianceRevenueReblozylMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:AllianceRevenueReblozylMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:AllianceRevenueReblozylMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:AllianceRevenueReblozylMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:AllianceRevenueReblozylMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:PharmaceuticalsegmentMembermrk:GardasilGardasil9Memberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:GardasilGardasil9Membermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:GardasilGardasil9Memberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:PharmaceuticalsegmentMembermrk:GardasilGardasil9Memberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:GardasilGardasil9Membermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:GardasilGardasil9Memberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:PharmaceuticalsegmentMembermrk:GardasilGardasil9Memberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:GardasilGardasil9Membermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:GardasilGardasil9Memberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:PharmaceuticalsegmentMembermrk:GardasilGardasil9Memberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:GardasilGardasil9Membermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:GardasilGardasil9Memberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:ProQuadMMRIIVarivaxMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:RotateqMember2022-07-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:RotateqMember2022-07-012022-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:RotateqMember2022-07-012022-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:RotateqMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:RotateqMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:RotateqMember2021-07-012021-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:RotateqMember2022-01-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:RotateqMember2022-01-012022-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:RotateqMember2022-01-012022-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:RotateqMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:RotateqMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:RotateqMember2021-01-012021-09-300000310158mrk:Pneumovax23Membercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:Pneumovax23Membermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:Pneumovax23Membermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:Pneumovax23Membercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:Pneumovax23Membermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:Pneumovax23Membermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:Pneumovax23Membercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:Pneumovax23Membermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:Pneumovax23Membermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:Pneumovax23Membercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:Pneumovax23Membermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:Pneumovax23Membermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:VaqtaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:VaqtaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:VaqtaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:VaqtaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:VaqtaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:VaqtaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:VaqtaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:VaqtaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:VaqtaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:VaqtaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:VaqtaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:VaqtaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:BridionMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:BridionMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:BridionMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:BridionMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:BridionMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:BridionMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:BridionMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:BridionMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:BridionMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:BridionMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:BridionMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:BridionMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:PrevymisMember2022-07-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PrevymisMember2022-07-012022-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:PrevymisMember2022-07-012022-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:PrevymisMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PrevymisMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:PrevymisMember2021-07-012021-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:PrevymisMember2022-01-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PrevymisMember2022-01-012022-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:PrevymisMember2022-01-012022-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:PrevymisMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:PrevymisMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:PrevymisMember2021-01-012021-09-300000310158country:USmrk:DificidMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:DificidMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:DificidMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:DificidMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:DificidMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:DificidMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:DificidMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:DificidMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:DificidMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:DificidMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:DificidMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:DificidMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:PrimaxinMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:PrimaxinMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:PrimaxinMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:PrimaxinMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PrimaxinMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PrimaxinMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:PrimaxinMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:PrimaxinMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:PrimaxinMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:PrimaxinMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PrimaxinMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PrimaxinMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:NoxafilMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:NoxafilMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:NoxafilMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:NoxafilMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:NoxafilMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:NoxafilMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:NoxafilMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:NoxafilMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:NoxafilMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:NoxafilMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:NoxafilMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:NoxafilMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:PharmaceuticalsegmentMembermrk:InvanzMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:InvanzMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InvanzMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:PharmaceuticalsegmentMembermrk:InvanzMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:InvanzMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InvanzMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:PharmaceuticalsegmentMembermrk:InvanzMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:InvanzMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InvanzMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:PharmaceuticalsegmentMembermrk:InvanzMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMembermrk:InvanzMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InvanzMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:CancidasMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:CancidasMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:CancidasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:CancidasMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:CancidasMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:CancidasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:CancidasMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:CancidasMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:CancidasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:CancidasMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:CancidasMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:CancidasMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:ZerbaxaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:ZerbaxaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:ZerbaxaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:ZerbaxaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:ZerbaxaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:ZerbaxaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:ZerbaxaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:ZerbaxaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:ZerbaxaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:ZerbaxaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:ZerbaxaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:ZerbaxaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:AllianceRevenueAdempasVerquvoMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:AllianceRevenueAdempasVerquvoMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:AllianceRevenueAdempasVerquvoMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:AllianceRevenueAdempasVerquvoMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:AllianceRevenueAdempasVerquvoMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:AdempasMember2022-07-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:AdempasMember2022-07-012022-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:AdempasMember2022-07-012022-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:AdempasMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:AdempasMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:AdempasMember2021-07-012021-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:AdempasMember2022-01-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:AdempasMember2022-01-012022-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:AdempasMember2022-01-012022-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:AdempasMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMembermrk:AdempasMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMembermrk:AdempasMember2021-01-012021-09-300000310158country:USmrk:LagevrioMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:LagevrioMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:LagevrioMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:LagevrioMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:LagevrioMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:LagevrioMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:LagevrioMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:LagevrioMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:LagevrioMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:LagevrioMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:LagevrioMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:LagevrioMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:IsentressIsentressHDMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:BelsomraMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:BelsomraMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:BelsomraMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:BelsomraMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:BelsomraMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:BelsomraMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:BelsomraMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:BelsomraMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:BelsomraMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:BelsomraMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:BelsomraMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:BelsomraMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:SimponiMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:SimponiMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:SimponiMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:SimponiMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:SimponiMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:SimponiMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:SimponiMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:SimponiMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:SimponiMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:SimponiMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:SimponiMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:SimponiMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:RemicadeMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:RemicadeMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:RemicadeMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:RemicadeMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:RemicadeMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:RemicadeMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:RemicadeMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:RemicadeMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:RemicadeMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:RemicadeMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:RemicadeMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:RemicadeMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:JanuviaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:JanuviaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:JanuviaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:JanuviaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:JanuviaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:JanuviaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:JanuviaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:JanuviaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:JanuviaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:JanuviaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:JanuviaMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:JanuviaMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:JanumetMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:JanumetMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:JanumetMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:JanumetMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:JanumetMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:JanumetMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:JanumetMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:JanumetMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:JanumetMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:JanumetMembercountry:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:JanumetMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:JanumetMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:OtherPharmaceuticalMembermrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:PharmaceuticalsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:LivestockMembercountry:USmrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:LivestockMembermrk:AnimalHealthsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:LivestockMembermrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:LivestockMembercountry:USmrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:LivestockMembermrk:AnimalHealthsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:LivestockMembermrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:LivestockMembercountry:USmrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:LivestockMembermrk:AnimalHealthsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:LivestockMembermrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:LivestockMembercountry:USmrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:LivestockMembermrk:AnimalHealthsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:LivestockMembermrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:AnimalHealthsegmentMembermrk:CompanionAnimalsMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:AnimalHealthsegmentMembermrk:InternationalMembermrk:CompanionAnimalsMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:AnimalHealthsegmentMembermrk:CompanionAnimalsMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:AnimalHealthsegmentMembermrk:CompanionAnimalsMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:AnimalHealthsegmentMembermrk:InternationalMembermrk:CompanionAnimalsMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:AnimalHealthsegmentMembermrk:CompanionAnimalsMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:AnimalHealthsegmentMembermrk:CompanionAnimalsMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:AnimalHealthsegmentMembermrk:InternationalMembermrk:CompanionAnimalsMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:AnimalHealthsegmentMembermrk:CompanionAnimalsMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:AnimalHealthsegmentMembermrk:CompanionAnimalsMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:AnimalHealthsegmentMembermrk:InternationalMembermrk:CompanionAnimalsMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:AnimalHealthsegmentMembermrk:CompanionAnimalsMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USmrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:AnimalHealthsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USmrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:AnimalHealthsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USmrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:AnimalHealthsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USmrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:AnimalHealthsegmentMembermrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:AnimalHealthsegmentMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158us-gaap:OperatingSegmentsMember2022-07-012022-09-300000310158country:USus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158us-gaap:OperatingSegmentsMember2021-07-012021-09-300000310158country:USus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158us-gaap:OperatingSegmentsMember2022-01-012022-09-300000310158country:USus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158mrk:InternationalMemberus-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158us-gaap:OperatingSegmentsMember2021-01-012021-09-300000310158country:USus-gaap:CorporateNonSegmentMember2022-07-012022-09-300000310158mrk:InternationalMemberus-gaap:CorporateNonSegmentMember2022-07-012022-09-300000310158us-gaap:CorporateNonSegmentMember2022-07-012022-09-300000310158country:USus-gaap:CorporateNonSegmentMember2021-07-012021-09-300000310158mrk:InternationalMemberus-gaap:CorporateNonSegmentMember2021-07-012021-09-300000310158us-gaap:CorporateNonSegmentMember2021-07-012021-09-300000310158country:USus-gaap:CorporateNonSegmentMember2022-01-012022-09-300000310158mrk:InternationalMemberus-gaap:CorporateNonSegmentMember2022-01-012022-09-300000310158us-gaap:CorporateNonSegmentMember2022-01-012022-09-300000310158country:USus-gaap:CorporateNonSegmentMember2021-01-012021-09-300000310158mrk:InternationalMemberus-gaap:CorporateNonSegmentMember2021-01-012021-09-300000310158us-gaap:CorporateNonSegmentMember2021-01-012021-09-300000310158country:US2022-07-012022-09-300000310158mrk:InternationalMember2022-07-012022-09-300000310158country:US2021-07-012021-09-300000310158mrk:InternationalMember2021-07-012021-09-300000310158country:US2022-01-012022-09-300000310158mrk:InternationalMember2022-01-012022-09-300000310158country:US2021-01-012021-09-300000310158mrk:InternationalMember2021-01-012021-09-300000310158us-gaap:EMEAMember2022-07-012022-09-300000310158us-gaap:EMEAMember2021-07-012021-09-300000310158us-gaap:EMEAMember2022-01-012022-09-300000310158us-gaap:EMEAMember2021-01-012021-09-300000310158country:CN2022-07-012022-09-300000310158country:CN2021-07-012021-09-300000310158country:CN2022-01-012022-09-300000310158country:CN2021-01-012021-09-300000310158country:JP2022-07-012022-09-300000310158country:JP2021-07-012021-09-300000310158country:JP2022-01-012022-09-300000310158country:JP2021-01-012021-09-300000310158srt:AsiaPacificMember2022-07-012022-09-300000310158srt:AsiaPacificMember2021-07-012021-09-300000310158srt:AsiaPacificMember2022-01-012022-09-300000310158srt:AsiaPacificMember2021-01-012021-09-300000310158srt:LatinAmericaMember2022-07-012022-09-300000310158srt:LatinAmericaMember2021-07-012021-09-300000310158srt:LatinAmericaMember2022-01-012022-09-300000310158srt:LatinAmericaMember2021-01-012021-09-300000310158mrk:OtherCountriesMember2022-07-012022-09-300000310158mrk:OtherCountriesMember2021-07-012021-09-300000310158mrk:OtherCountriesMember2022-01-012022-09-300000310158mrk:OtherCountriesMember2021-01-012021-09-300000310158us-gaap:MaterialReconcilingItemsMember2022-07-012022-09-300000310158us-gaap:MaterialReconcilingItemsMember2021-07-012021-09-300000310158us-gaap:MaterialReconcilingItemsMember2022-01-012022-09-300000310158us-gaap:MaterialReconcilingItemsMember2021-01-012021-09-30


UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
 
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2022
OR
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ______ to ______
Commission File No. 1-6571
Merck & Co., Inc.
(Exact name of registrant as specified in its charter)
New Jersey22-1918501
(State or other jurisdiction of incorporation)
(I.R.S. Employer Identification No.)
126 East Lincoln Avenue
RahwayNew Jersey07065
(Address of principal executive offices) (zip code)
(Registrant’s telephone number, including area code) (908) 740-4000
Not Applicable
(Former name, former address and former fiscal year, if changed since last report.)
Securities Registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock ($0.50 par value)MRKNew York Stock Exchange
0.500% Notes due 2024MRK 24New York Stock Exchange
1.875% Notes due 2026MRK/26New York Stock Exchange
2.500% Notes due 2034MRK/34New York Stock Exchange
1.375% Notes due 2036MRK 36ANew York Stock Exchange

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.  Yes     No  
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).  Yes     No  
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):
Large accelerated filerAccelerated filer
Non-accelerated filerSmaller reporting company
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes ☐  No 
The number of shares of common stock outstanding as of the close of business on October 31, 2022: 2,535,395,974





Table of Contents





Part I - Financial Information
Item 1. Financial Statements
MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF INCOME
(Unaudited, $ in millions except per share amounts)
 
 Three Months Ended
September 30,
Nine Months Ended
September 30,
 2022202120222021
Sales$14,959 $13,154 $45,453 $35,183 
Costs, Expenses and Other
Cost of sales3,934 3,450 13,530 9,752 
Selling, general and administrative2,520 2,336 7,355 6,804 
Research and development4,399 2,445 9,773 9,177 
Restructuring costs94 107 288 487 
Other (income) expense, net429 (450)1,576 (1,007)
 11,376 7,888 32,522 25,213 
Income from Continuing Operations Before Taxes3,583 5,266 12,931 9,970 
Taxes on Income from Continuing Operations330 695 1,423 1,436 
Net Income from Continuing Operations3,253 4,571 11,508 8,534 
Less: Net Income Attributable to Noncontrolling Interests5 4 6 9 
Net Income from Continuing Operations Attributable to Merck & Co., Inc.3,248 4,567 11,502 8,525 
Income from Discontinued Operations, Net of Taxes and Amounts Attributable to Noncontrolling Interests   766 
Net Income Attributable to Merck & Co., Inc.$3,248 $4,567 $11,502 $9,291 
Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations$1.28 $1.81 $4.55 $3.37 
Income from Discontinued Operations   0.30 
Net Income$1.28 $1.81 $4.55 $3.67 
Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders:
Income from Continuing Operations$1.28 $1.80 $4.53 $3.36 
Income from Discontinued Operations   0.30 
Net Income$1.28 $1.80 $4.53 $3.66 
 
MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME
(Unaudited, $ in millions)
 
 Three Months Ended
September 30,
Nine Months Ended
September 30,
 2022202120222021
Net Income Attributable to Merck & Co., Inc.$3,248 $4,567 $11,502 $9,291 
Other Comprehensive (Loss) Income Net of Taxes:
Net unrealized gain on derivatives, net of reclassifications338 84 584 324 
Benefit plan net (loss) gain and prior service (cost) credit, net of amortization(186)38 92 1,522 
Cumulative translation adjustment
(568)(84)(990)(251)
 (416)38 (314)1,595 
Comprehensive Income Attributable to Merck & Co., Inc.$2,832 $4,605 $11,188 $10,886 
 The accompanying notes are an integral part of these condensed consolidated financial statements.
- 3 -



MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEET
(Unaudited, $ in millions except per share amounts)
 
September 30, 2022December 31, 2021
Assets
Current Assets
Cash and cash equivalents
$11,145 $8,096 
Short-term investments103  
Accounts receivable (net of allowance for doubtful accounts of $77 in 2022
 and $62 in 2021)
9,482 9,230 
Inventories (excludes inventories of $2,641 in 2022 and $2,194 in 2021
classified in Other assets - see Note 7)
5,614 5,953 
Other current assets
7,217 6,987 
Total current assets33,561 30,266 
Investments984 370 
Property, Plant and Equipment, at cost, net of accumulated depreciation of $17,921
in 2022 and $18,192 in 2021
20,424 19,279 
Goodwill21,160 21,264 
Other Intangibles, Net21,368 22,933 
Other Assets9,584 11,582 
 $107,081 $105,694 
Liabilities and Equity
Current Liabilities
Loans payable and current portion of long-term debt
$1,936 $2,412 
Trade accounts payable
3,371 4,609 
Accrued and other current liabilities
14,222 13,859 
Income taxes payable
1,698 1,224 
Dividends payable
1,771 1,768 
Total current liabilities22,998 23,872 
Long-Term Debt28,482 30,690 
Deferred Income Taxes2,417 3,441 
Other Noncurrent Liabilities8,660 9,434 
Merck & Co., Inc. Stockholders’ Equity
Common stock, $0.50 par value
Authorized - 6,500,000,000 shares
Issued - 3,577,103,522 shares in 2022 and 2021
1,788 1,788 
Other paid-in capital
44,243 44,238 
Retained earnings
59,928 53,696 
Accumulated other comprehensive loss
(4,743)(4,429)
101,216 95,293 
Less treasury stock, at cost:
1,043,697,097 shares in 2022 and 1,049,499,023 shares in 2021
56,758 57,109 
Total Merck & Co., Inc. stockholders’ equity44,458 38,184 
Noncontrolling Interests66 73 
Total equity44,524 38,257 
 $107,081 $105,694 
The accompanying notes are an integral part of this condensed consolidated financial statement.
- 4 -



MERCK & CO., INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS
(Unaudited, $ in millions)
 
 Nine Months Ended
September 30,
 20222021
Cash Flows from Operating Activities of Continuing Operations
Net income from continuing operations$11,508 $8,534 
Adjustments to reconcile net income from continuing operations to net cash provided by operating activities of continuing operations:
Amortization1,623 1,231 
Depreciation1,394 1,148 
Intangible asset impairment charges910  
Loss (income) from investments in equity securities, net1,361 (1,535)
Charge for the acquisition of Pandion Therapeutics, Inc. 1,556 
Deferred income taxes
(1,261)28 
Share-based compensation
396 360 
Other
1,169 499 
Net changes in assets and liabilities
(2,435)(3,794)
Net Cash Provided by Operating Activities of Continuing Operations14,665 8,027 
Cash Flows from Investing Activities of Continuing Operations
Capital expenditures(3,239)(3,240)
Purchases of securities and other investments(710)(1)
Proceeds from sales of securities and other investments709 497 
Acquisition of Pandion Therapeutics, Inc., net of cash acquired (1,554)
Other acquisitions, net of cash acquired(121)(89)
Other149 15 
Net Cash Used in Investing Activities of Continuing Operations(3,212)(4,372)
Cash Flows from Financing Activities of Continuing Operations
Net change in short-term borrowings (3,983)
Payments on debt(2,250)(1,153)
Distribution from Organon & Co. 9,000 
Purchases of treasury stock (822)
Dividends paid to stockholders(5,262)(4,967)
Proceeds from exercise of stock options119 68 
Other(172)(253)
Net Cash Used in Financing Activities of Continuing Operations(7,565)(2,110)
Cash Flows from Discontinued Operations
Net cash provided by operating activities 1,051 
Net cash used in investing activities (134)
Net cash used in financing activities (504)
Net Cash Flows Provided by Discontinued Operations 413 
Effect of Exchange Rate Changes on Cash, Cash Equivalents and Restricted Cash(776)(65)
Net Increase in Cash, Cash Equivalents and Restricted Cash3,112 1,893 
Cash, Cash Equivalents and Restricted Cash at Beginning of Year (includes restricted cash of
$71 and $103 at January 1, 2022 and 2021, respectively, included in Other current assets)
8,167 8,153 
Cash, Cash Equivalents and Restricted Cash at End of Period (includes restricted cash of $134
and $30 at September 30, 2022 and 2021, respectively, included in Other current assets)
$11,279 $10,046 
The accompanying notes are an integral part of this condensed consolidated financial statement.
- 5 -

Notes to Condensed Consolidated Financial Statements (unaudited)

1. Basis of Presentation
The accompanying unaudited condensed consolidated financial statements of Merck & Co., Inc. (Merck or the Company) have been prepared pursuant to the rules and regulations for reporting on Form 10-Q. Accordingly, certain information and disclosures required by accounting principles generally accepted in the United States (U.S.) (GAAP) for complete consolidated financial statements are not included herein. These interim statements should be read in conjunction with the audited financial statements and notes thereto included in Merck’s Form 10-K filed on February 25, 2022.
The results of operations of any interim period are not necessarily indicative of the results of operations for the full year. In the Company’s opinion, all adjustments necessary for a fair statement of these interim statements have been included and are of a normal and recurring nature.
Spin-Off of Organon & Co.
On June 2, 2021, Merck completed the spin-off of products from its women’s health, biosimilars and established brands businesses into a new, independent, publicly traded company named Organon & Co. (Organon) through a distribution of Organon’s publicly traded stock to Company shareholders. The distribution is expected to qualify and has been treated as tax-free to the Company and its shareholders for U.S. federal income tax purposes. The established brands included in the transaction consisted of dermatology, non-opioid pain management, respiratory, select cardiovascular products, as well as the rest of Merck’s diversified brands franchise. Merck’s existing research pipeline programs continue to be owned and developed within Merck as planned. The historical results of the businesses that were contributed to Organon in the spin-off have been reflected as discontinued operations in the Company’s consolidated financial statements through the date of the spin-off (see Note 2).
Recently Adopted Accounting Standards
In August 2020, the Financial Accounting Standards Board (FASB) issued amended guidance on the accounting for convertible instruments and contracts in an entity’s own equity. The guidance removes the separation model for convertible debt instruments and preferred stock, amends requirements for conversion options to be classified in equity as well as amends diluted earnings per share (EPS) calculations for certain convertible debt instruments. The Company adopted the new guidance on January 1, 2022 using a modified retrospective approach. There was no impact to the Company’s consolidated financial statements upon adoption.
In November 2021, the FASB issued new guidance to increase the transparency of transactions with a government that are accounted for by applying a grant or contribution accounting model by analogy. The guidance requires annual disclosures of such transactions to include the nature of the transactions and the significant terms and conditions, the accounting treatment and the impact to a company’s financial statements. The Company adopted the new guidance on January 1, 2022 on a prospective basis. There was no material impact to the Company’s consolidated financial statements upon adoption.
In March 2020, the FASB issued optional guidance to ease the potential burden in accounting for (or recognizing the effects of) reference rate reform on financial reporting and subsequently issued clarifying amendments. The guidance provides optional expedients and exceptions for accounting for contracts, hedging relationships, and other transactions that reference the London Interbank Offered Rate (LIBOR) or another reference rate expected to be discontinued because of reference rate reform. The Company adopted the optional guidance on July 1, 2022 on a prospective basis. There was no material impact to the Company’s consolidated financial statements upon adoption.
Recently Issued Accounting Standards Not Yet Adopted
In October 2021, the FASB issued amended guidance that requires acquiring entities to recognize and measure contract assets and liabilities in a business combination in accordance with existing revenue recognition guidance. The amended guidance is effective for interim and annual periods in 2023 and is to be applied prospectively. Early adoption is permitted on a retrospective basis to the beginning of the fiscal year of adoption. The adoption of this guidance will not have an impact on the Company’s consolidated financial statements for prior acquisitions; however, the impact in future periods will be dependent upon the contract assets and contract liabilities acquired in future business combinations.
In June 2022, the FASB issued guidance related to the fair value measurement of an equity security subject to contractual restrictions that prohibit the sale of the equity security. The new guidance also introduces new disclosure requirements for equity securities subject to contractual sale restrictions that are measured at fair value. The amended guidance is effective for interim and annual periods in 2024 and is to be applied prospectively. Early adoption is permitted for both interim and annual periods. The Company is currently evaluating the impact of adoption on its consolidated financial statements.
- 6 -

Notes to Condensed Consolidated Financial Statements (unaudited)
2. Spin-Off of Organon & Co.
On June 2, 2021, Merck completed the spin-off of Organon through a distribution of Organon’s publicly traded stock to Company shareholders. In connection with the spin-off, each Merck shareholder received one tenth of a share of Organon’s common stock for each share of Merck common stock held by such shareholder. The distribution is expected to qualify and has been treated as tax free to Merck and its shareholders for U.S. federal income tax purposes. Indebtedness of $9.5 billion principal amount, consisting of term loans and senior notes, was issued in 2021 in connection with the spin-off and assumed by Organon. Merck is no longer the obligor of any Organon debt or financing arrangements. Cash proceeds of $9.0 billion were distributed by Organon to Merck in connection with the spin-off.
Also in connection with the spin-off, Merck and Organon entered into a separation and distribution agreement and also entered into various other agreements to effect the spin-off and provide a framework for the relationship between Merck and Organon after the spin-off, including a transition services agreement (TSA), manufacturing and supply agreements (MSAs), trademark license agreements, intellectual property license agreements, an employee matters agreement, a tax matters agreement and certain other commercial agreements. Under the TSA, Merck is providing Organon various services and, similarly, Organon is providing Merck various services. The provision of services under the TSA generally will terminate within 25 months following the spin-off; however, the provision of certain services has been extended to 31 months. Merck and Organon also entered into a series of interim operating agreements pursuant to which in various jurisdictions where Merck held licenses, permits and other rights in connection with marketing, import and/or distribution of Organon products prior to the separation, Merck is continuing to market, import and distribute such products until such time as the relevant licenses and permits are transferred to Organon. Under such interim operating agreements and in accordance with the separation and distribution agreement, Merck is continuing operations in the affected markets on behalf of Organon, with Organon receiving all of the economic benefits and burdens of such activities. Additionally, Merck and Organon entered into a number of MSAs pursuant to which Merck is (a) manufacturing and supplying certain active pharmaceutical ingredients for Organon, (b) manufacturing and supplying certain formulated pharmaceutical products for Organon, and (c) packaging and labeling certain finished pharmaceutical products for Organon. Similarly, Organon and Merck entered into a number of MSAs pursuant to which Organon is (a) manufacturing and supplying certain formulated pharmaceutical products for Merck, and (b) packaging and labeling certain finished pharmaceutical products for Merck. The terms of the MSAs range in initial duration from four years to ten years.
The amounts included in the condensed consolidated statement of income for the above MSAs include sales of $100 million and $293 million and related cost of sales of $104 million and $312 million for the three and nine months ended September 30, 2022, respectively. The amounts included in the condensed consolidated statement of income for the MSAs in the same periods of 2021 were immaterial. Amounts included in the condensed consolidated statement of income for the TSAs were immaterial for the three and nine months ended September 30, 2022 and September 30, 2021.
The amounts due from Organon under all of the above agreements were $567 million and $964 million at September 30, 2022 and December 31, 2021, respectively, and are reflected in Other current assets. The amounts due to Organon under these agreements were $333 million and $